Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
Published on: December 15, 2023
Oral Contraceptive Use and Acute Ischemic Stroke Risk in Patients with Moyamoya Disease
Shoko Hara1, Shota Takahashi1, Ayako Fudono2
1Department of Neurosurgery, Institute of Science Tokyo, Tokyo, Japan.
None:
To investigate whether oral contraceptives induce acute ischemic stroke in patients with moyamoya disease. We retrospectively reviewed female patients with moyamoya disease who were taking oral contraceptives during their reproductive years (12-49 years of age) at the time of diagnosis or during follow-up. The patients' detailed clinical history, including the time course of oral contraceptive usage and acute ischemic stroke occurrence, was evaluated. For patients with radiological evidence of acute ischemic stroke, the imaging pattern of stroke was assessed to investigate the underlying mechanisms. Among 589 female patients, 12 patients took oral contraceptives at some point during the period from 2012 to 2023; 5 patients were taking oral contraceptives at the time of diagnosis, and 4 of them were diagnosed with moyamoya disease after acute ischemic stroke. Among the 7 patients who started oral contraceptives during follow-up, 2 patients developed acute ischemic stroke several months after starting oral contraceptives. Notably, none of the hemispheres that developed acute ischemic stroke previously underwent revascularization, and none of the 5 hemispheres with prior revascularization developed acute ischemic stroke. The imaging pattern of acute ischemic stroke in 7 patients suggested the contribution of a thromboembolic mechanism. Oral contraceptives may increase the risk of acute ischemic stroke via thromboembolic mechanisms in patients with moyamoya disease, but its risk might be manageable in hemispheres with prior revascularization and stable disease conditions for years. Active education of patients regarding the possible risk of oral contraceptives and close communication with gynecologists seem necessary to provide the best treatment strategies for female patients with moyamoya disease who require contraception or treatment of menstrual disorders.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

